QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.106.030254v1 71/3/704    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Frauli, M. Articles by Prézeau, L. Search for Related Content PubMed PubMed Citation Articles by Frauli, M. Articles by Prézeau, L.

Amino-Pyrrolidine Tricarboxylic Acids Give New Insight into Group III Metabotropic Glutamate Receptor Activation Mechanism

Faust Pharmaceuticals SA, Illkirch-Graffenstaden, France (M.F., N.H., S.S., P.N.); Département de Pharmacologie Moléculaire, Institut de Génomique Fonctionnelle; Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche (UMR) 5203, Institut National de la Santé et de la Recherche Médicale U661, Université Montpellier I, and Université Montpellier II, Montpellier, France (M.F., J.-P.P., L.P.); Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques; CNRS UMR 8601, Université René Descartes-Paris V, Paris, France (N.T., F.A.); and Accelrys SA, Orsay, France (N.T., H.-O.B.).

Like most class C G-protein-coupled receptors, metabotropic glutamate (mGlu) receptors possess a large extracellular domain where orthosteric ligands bind. Crystal structures revealed that this domain, called Venus FlyTrap (VFT), adopts a closed or open conformation upon agonist or antagonist binding, respectively. We have described amino-pyrrolidine tricarboxylic acids (APTCs), including (2S,4S)-4-amino-1-[(E)-3-carboxyacryloyl]pyrrolidine-2,4-dicarboxylic acid (FP0429), as new selective group III mGlu agonists. Whereas FP0429 is an almost full mGlu4 agonist, it is a weak and partial agonist of the closely related mGlu8 subtype. To get more insight into the activation mechanism of mGlu receptors, we aimed to elucidate why FP0429 behaves differently at these two highly homologous receptors by focusing on two residues within the binding site that differ between mGlu4 and mGlu8. Site-directed mutagenesis of Ser157 and Gly158 of mGlu4 into their mGlu8 homologs (Ala) turned FP0429 into a weak partial agonist. Conversely, introduction of Ser and Gly residues into mGlu8 increased FP0429 efficacy. Docking of FP0429 in mGlu4 VFT 3D model helped us characterize the role of each residue. Indeed, mGlu4 Ser157 seems to have an important role in FP0429 binding, whereas Gly158 may allow a deeper positioning of this agonist in the cavity of lobe I, thereby ensuring optimal interactions with lobe II residues in the fully closed state of the VFT. In contrast, the presence of a methyl group in mGlu8 (Ala instead of Gly) weakens the interactions with the lobe II residues. This probably results in a less stable or a partially closed form of the mGlu8 VFT, leading to partial receptor activation.

Address correspondence to: Laurent Prézeau, Institut de Génomique Fonctionnelle, 141, rue de la Cardonille, 34094 Montpellier, France. E-mail: laurent.prezeau{at}igf.cnrs.fr

This article has been cited by other articles:

				X. Rovira, D. Roche, J. Serra, J. Kniazeff, J.-P. Pin, and J. Giraldo Modeling the Binding and Function of Metabotropic Glutamate Receptors J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 443 - 456. [Abstract] [Full Text] [PDF]